Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Teva
Federal Trade Commission
Covington
Baxter
Argus Health
Queensland Health
Healthtrust
Express Scripts

Generated: June 23, 2018

DrugPatentWatch Database Preview

ULTIVA Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Ultiva, and what generic alternatives are available?

Ultiva is a drug marketed by Mylan Institutional and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

The generic ingredient in ULTIVA is remifentanil hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the remifentanil hydrochloride profile page.
Drug patent expirations by year for ULTIVA
Pharmacology for ULTIVA
Drug ClassOpioid Agonist
Mechanism of ActionFull Opioid Agonists
Synonyms for ULTIVA
1-Piperidinepropanoic acid, 4-(methoxycarbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester, monohydrochloride
132539-07-2
132875-61-7 (Parent)
3-[methoxycarbonyl-4-[(1-oxopropyl)phenylamino]1-piperidine]propanoic acid methyl ester hydrochloride
4-(Methoxycarbonyl)-4-[(1-oxopropyl)phenylamino]-1-piperidinepropanoic Acid Methyl Ester Hydrochloride
4-Carboxy-4-(N-phenylpropionamido)-1-piperidine propionic acid, dimethyl ester, monohydrochloride
5V444H5WIC
AC1L1TZ5
AC1Q3E9W
C20H28N2O5.HCl
CHEBI:32091
CHEMBL1201120
D01177
DTXSID50157614
FT-0674340
GI 87084B
GI-87084B
HE306791
LS-172838
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate hydrochloride
methyl-1-(3-methoxy-3-oxopropyl)-4-[phenyl(propanoyl)amino]piperidin-4-carboxylathydrochlorid
Remifentanil HCl
REMIFENTANIL HYDROCHLORIDE
Remifentanil hydrochloride (JAN/USAN)
Remifentanil hydrochloride [USAN]
Remifentanil hydrochloride solution, 100 mug/mL in methanol (as free base), certified reference material
Remifentanil hydrochloride, >=97% (HPLC), powder
Remifentanil hydrochloride, European Pharmacopoeia (EP) Reference Standard
remifentanil monohydrochloride
Remifentanyl Hydrochloride
SCHEMBL41242
UNII-5V444H5WIC

US Patents and Regulatory Information for ULTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 AP RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 AP RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for ULTIVA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ULTIVA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe for Injection 1 mg/vial, 2 mg/vial and 5 mg/vial ➤ Subscribe 2013-12-27

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Merck
Healthtrust
Julphar
Express Scripts
Baxter
Cerilliant
Citi
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.